Applying Disease Modifying Inclusion/Exclusion Criteria to National
Alzheimer?#128#153s Disease Coordinating Center (NACC) Participants 
   Lead Investigator:    Aaron Ritter
   Institution      :    Cleveland Clinic - Las Vegas
   E-Mail           :    rittera@ccf.org
   Proposal ID      :    1631



   Proposal Description:
   Several new amyloid-targeted, disease-modifying therapeutics may soon be approved for clinical use. The clinical trials upon which approval will be granted (i.e. the recent EMERGE and ENGAGE studies), however, have increasingly utilized narrow inclusion/exclusion criteria that may limit the generalizability of these clinical trials to the broader population afflicted by AD. The specific aim of our research project is to determine the percentage of individuals in the NACC database with evidence of amyloid pathology (either on neuropathology or cerebrospinal fluid) who would have been provisionally eligible to participate in the recent EMERGE/EMERGE clinical trials (the inclusion/exclusion criteria are publicly available) based on their clinical, demographic, and neuropsychological test performance at their first research visit. We will also determine the clinical and demographic features of AD patients who would have been deemed ineligible for participation in these trials.